PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2025 17:26 ET | Source: PDS Biotechnology Corporation Phase 2:…
